癌症研究
Janus激酶2
贾纳斯激酶
癌基因
车站3
细胞周期
JAK-STAT信号通路
信号转导
细胞生长
结直肠癌
癌变
个人识别码1
医学
细胞凋亡
磷酸化
生物
癌症
细胞生物学
内科学
酪氨酸激酶
生物化学
丝氨酸
作者
Shuwei Wang,Jun Hu,Qinhao Guo,Yan Fang Zhao,JIE-JING CHENG,Dongsheng Zhang,QIANG FEI,Juan Li,Yueming Sun
摘要
Interleukin (IL)-6 and the downstream Janus kinase (JAK)/signal activator of transcription (STAT) pathway have been found to be important in the development of colorectal cancer (CRC). To develop novel therapies for CRC, we have explored the effects of a novel small-molecule JAK inhibitor (AZD1480) on IL-6/JAK/STAT3 pathway and its potential antitumor activity on the human CRC cell lines (HCT116, HT29 and SW480). The results showed that, AZD1480 effectively prevents constitutive and IL-6-induced JAK2 and STAT-3 phosphorylation and exerted antitumor functional effects by a decrease in proliferation and an increase in apoptosis in CRC cells. The inhibition of tumorigenesis was consistent with the decreased phosphorylated JAK2 and phosphorylated STAT3, and the decreased expression of STAT3‑targeted genes c-Myc, cyclin D2 and IL-6. Thus, AZD1480 is a potential new clinical therapeutic agent for patients with CRC.
科研通智能强力驱动
Strongly Powered by AbleSci AI